Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HAMILTON PHARMA HAS TWO-THIRDS OF NAPROXEN MARKET

Executive Summary

HAMILTON PHARMA HAS TWO-THIRDS OF NAPROXEN MARKET in January, Hamilton parent Syntex reported Feb. 24. "Of the new prescriptions filled for the naproxen molecule in January 1994," Syntex said, "64% were filled with generic naproxen sold by Hamilton Pharma, Inc., 31% were filled with branded Naprosyn and 5% were filled with generic naproxen sold by non-related companies."

You may also be interested in...



Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch

Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel